Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan

Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.

Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets

Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)

Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows

New mass spectrometry instrument and consumables launch during IMSC 2022